Definitive radiotherapy for localized follicular lymphoma staged by

Adult Aged Aged, 80 and over Female Fluorodeoxyglucose F18 Follow-Up Studies Humans Lymphoma, Follicular / diagnostic imaging Male Middle Aged Neoplasm Recurrence, Local / diagnostic imaging Positron Emission Tomography Computed Tomography / standards Prognosis Radiopharmaceuticals Radiotherapy / mortality Retrospective Studies Survival Rate Young Adult

Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
17 01 2019
Historique:
received: 18 04 2018
accepted: 31 10 2018
pubmed: 18 11 2018
medline: 21 8 2019
entrez: 18 11 2018
Statut: ppublish

Résumé

Radiotherapy (RT) can be curative in patients with localized follicular lymphoma (FL), with historical series showing a 10-year disease-free survival of 40 to 50%. As

Identifiants

DOI: 10.1182/blood-2018-04-843540 PMID: 30446493
pubmed: 30446493
pii: S0006-4971(20)42863-0
doi: 10.1182/blood-2018-04-843540
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

237-245

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2019 by The American Society of Hematology.

Auteurs

Jessica L Brady (JL)

Guy's Cancer Centre, Guy's and St Thomas' Hospital, London, United Kingdom.

Michael S Binkley (MS)

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.

Carla Hajj (C)

Memorial Sloan Kettering Cancer Center, New York, NY.

Monica Chelius (M)

Memorial Sloan Kettering Cancer Center, New York, NY.

Karen Chau (K)

Memorial Sloan Kettering Cancer Center, New York, NY.

Alex Balogh (A)

Tom Baker Cancer Center, Calgary, AB, Canada.

Mario Levis (M)

Department of Oncology, University of Torino, Torino, Italy.

Andrea Riccardo Filippi (AR)

Department of Oncology, University of Torino, Torino, Italy.

Michael Jones (M)

Princess Margaret Cancer Center, Toronto, ON, Canada.
ORCID: 0000-0002-8377-5383

Michael Mac Manus (M)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Trans-Tasman Radiation Oncology Group, Waratah, NSW, Australia.

Andrew Wirth (A)

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Masahiko Oguchi (M)

Cancer Institute Hospital, Tokyo, Japan.

Anders Krog Vistisen (AK)

Aalborg University Hospital, Aalborg, Denmark.

Therese Youssef Andraos (TY)

University of Texas MD Anderson Cancer Center, Houston, TX.

Andrea K Ng (AK)

Dana-Farber Cancer Center, Boston, MA.
Department of Radiation Oncology, Harvard University School of Medicine, Boston, MA.

Berthe M P Aleman (BMP)

Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Seo Hee Choi (SH)

Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.

Youlia Kirova (Y)

Institut Curie, Paris, France.

Sara Hardy (S)

Department of Radiation Oncology, University of Rochester, Rochester, NY; and.

Gabriele Reinartz (G)

Department of Radiation Oncology, Munster University, Munster, Germany.

Hans T Eich (HT)

Department of Radiation Oncology, Munster University, Munster, Germany.

Scott V Bratman (SV)

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.
ORCID: 0000-0001-8610-4908

Louis S Constine (LS)

Department of Radiation Oncology, University of Rochester, Rochester, NY; and.

Chang-Ok Suh (CO)

Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.

Bouthaina Dabaja (B)

University of Texas MD Anderson Cancer Center, Houston, TX.

Tarec C El-Galaly (TC)

Aalborg University Hospital, Aalborg, Denmark.

David C Hodgson (DC)

Princess Margaret Cancer Center, Toronto, ON, Canada.

Umberto Ricardi (U)

Department of Oncology, University of Torino, Torino, Italy.

Joachim Yahalom (J)

Memorial Sloan Kettering Cancer Center, New York, NY.

Richard T Hoppe (RT)

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.

N George Mikhaeel (NG)

Guy's Cancer Centre, Guy's and St Thomas' Hospital, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Definitive radiotherapy for localized...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Definitive radiotherapy for localized...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Definitive radiotherapy for localized...
questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › Definitive radiotherapy for localized...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Definitive radiotherapy for localized...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Definitive radiotherapy for localized...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome folliculaire › Definitive radiotherapy for localized...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Definitive radiotherapy for localized...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Definitive radiotherapy for localized...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Definitive radiotherapy for localized...
questionsmedicales.fr › Diagnostic › Pronostic › Definitive radiotherapy for localized...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Definitive radiotherapy for localized...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Definitive radiotherapy for localized...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Definitive radiotherapy for localized...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Definitive radiotherapy for localized...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Definitive radiotherapy for localized...